Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18707381 | 0.88 | NOTUM (0.42) | NOTUMROCK1MTNR1AHPGDSLC6A2 | |
| SCHEMBL19954697 | 0.88 | NOTUM (0.42) | NOTUMROCK1MTNR1AHPGDSLC6A2 | |
| SCHEMBL25879868 | 0.82 | LMNA (0.35) | NOTUMMTNR1ASLC6A2HTR2AHTR2C | |
| SCHEMBL28648154 | 0.77 | NOTUM (0.44) | NOTUMMTNR1AHPGDSLC6A2 | |
| SCHEMBL19230066 | 0.75 | NOTUM (0.36) | NOTUMROCK1MTNR1AHPGD | |
| SCHEMBL17831021 | 0.74 | ROCK1 (0.37) | NOTUMROCK1HPGD | |
| SCHEMBL17751517 | 0.74 | ROCK1 (0.37) | NOTUMROCK1MTNR1AHPGDSLC6A2 | |
| SCHEMBL17751472 | 0.73 | ROCK1 (0.39) | NOTUMROCK1HPGD | |
| SCHEMBL19954699 | 0.73 | ROCK1 (0.39) | NOTUMROCK1HPGD | |
| SCHEMBL17751482 | 0.73 | MEN1 (0.36) | NOTUMROCK1FPR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492749-B2 | Electroluminescent metal complexes with nucleophilic carbene ligands | BASF SE (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20110114922-A1 | Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands | UDC IRELAND LIMITED (IE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110114922-A1 | Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands | OCIAD1, OCIAD2, C1S | NOTUM 3755/4885MCL1 1435/4885ROCK1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.